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Background: There is no general agreement about whether patients who have already received neoadjuvant
chemoradiotherapy need further postoperative chemotherapy based on 5-fluorouracil(5-FU) or 5-FU plus oxaliplatin.
Methods: Medicare beneficiaries from 1992 to 2008 with Union for International Cancer Control ypStages I to III
primary carcinoma of the rectum who underwent 5-FU-based neoadjuvant chemoradiotherapy and surgery for
curative intent were identified through the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked
database. A Cox proportional hazards model and propensity score-matched techniques were used to evaluate the
effect of treatment on survival.
Results: For patients with resected rectal cancer who have already received 5-FU-based neoadjuvant chemoradiotherapy,
postoperative 5-FU-based chemotherapy did not prolong cancer-specific survival (CSS) in ypStage I (P = 0.960) and
ypStage II (P = 0.134); however, it significantly improved the CSS in ypStage III (hazard ratio = 1.547, 95% CI = 1.101-
2.173, P = 0.012). No significant differences in survival between the 5-FU group and oxaliplatin group were observed.
Conclusions: For patients with resected rectal cancer who have already received 5-FU-based neoadjuvant
chemoradiotherapy, postoperative 5-FU-based chemotherapy prolongs the CSS of groups in ypStage III. Adding
oxaliplatin to fluoropyrimidines in the postoperative chemotherapy did not improve the CSS for patients who
received neoadjuvant chemoradiotherapy.
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Rectal cancer has been defined as a cancerous lesion lo-
cated within 12 cm of the anal verge [1]. At present, the
main treatment for locally advanced rectal cancer is che-
moradiotherapy plus total mesorectal excision (TME).
Although it is debatable whether preoperative chemora-
diotherapy improves long-term survival [2-4], random-
ized clinical trials have shown better local control, lower
toxicity, and higher compliance if preoperative chemora-
diotherapy is administered rather than postoperative con-
ventionally fractionated chemoradiotherapy [5,6]. Thus,* Correspondence: josieon826@sina.cn
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unless otherwise stated.the current “gold standard” of treatment recommended
by both the National Comprehensive Cancer Network
(NCCN) [7] and the European Society for Medical
Oncology (ESMO) [8] for locally advanced rectal cancers
with invading through the muscularis propria into the
pericolorectal tissues (cT3), penetrating to the surface of
the visceral peritoneum (cT4a), invading or being adher-
ent to other organs or structures (cT4b), or lymph nodal
metastasis on imaging (cN1-2) is preoperative radiother-
apy plus 5-fluorouracil (5-FU)-based chemotherapy.
Is adjuvant chemotherapy needed after curative sur-
gery for rectal cancer patients who have received neoad-
juvant chemoradiotherapy? The NCCN recommended
postoperative chemotherapy for all patients undergoing
preoperative chemoradiotherapy regardless of the patho-
logical stage [7]. The ESMO guidelines state that “similar. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Stage II), adjuvant chemotherapy can be provided, even if
the scientific support for sufficient effect is less” [8]. How-
ever, several studies questioned the use of adjuvant
chemotherapy in patients with rectal cancer who under-
went neoadjuvant chemoradiotherapy and curative sur-
gery, especially in patients without pathological lymph
node metastasis (ypN0) [2,9-14]. Results from all these
studies showed that adding postoperative adjuvant chemo-
therapy did not significantly improve disease-free survival
(DFS) or overall survival (OS) in patients who have already
received neoadjuvant chemoradiotherapy. On the other
hand, a unique randomized clinical trial suggested that
good-prognosis patients (ypT0-2) benefit from postopera-
tive chemotherapy [15]. Furthermore, it was not reported
whether adding postoperative 5-FU-based chemotherapy
could improve the survival of patients with pathological
lymph node metastasis (ypN1-2). Hence, for patients who
have received neoadjuvant therapy, the role of postopera-
tive chemotherapy is still controversial.
Although lack of data from rigorous randomized clinical
trials confirmed the effectiveness, oxaliplatin has been
used in rectal cancer for several years based on the extrap-
olated data in colon cancer. Similarly, the role of postoper-
ative oxaliplatin in patients with rectal cancer who have
already received neoadjuvant chemoradiotherapy is still
not yet defined. To the best of our knowledge, only two
ongoing randomized clinical trials presented preliminary
results, though contradictory, on this issue [16,17].
The aim of the current study was to investigate whether
postoperative 5-FU-based chemotherapy or 5-FU plus
oxaliplatin provides a benefit for patients with resected




The data from the Surveillance, Epidemiology, and End
Results (SEER)–Medicare-linked database were exam-
ined. The approval and subsequent access to the data for
this study were granted by the National Cancer Institute
(NCI) and Information Management Services (IMS), Inc.
following submission of a formal data request outlining
the research objectives. Also, this study was approved by
the Institutional Review Board of the first hospital of
China Medical University.
The SEER cancer registries include information on pa-
tient demographics, tumor characteristics, first course
of treatment, and survival of patients who were newly
diagnosed with cancer. SEER regions included approxi-
mately 26% of the US population [18]. Medicare is the
primary health insurer for 97% of the US population
aged ≥65 years [19]. The details of the database were
presented elsewhere [20].Patient selection
All Medicare-enrolled patients aged ≥66 years that were
diagnosed with primary adenocarcinoma of the rectum
from 1992 to 2008 were included in the study (SEER can-
cer site codes: 19.9 and 20.9; SEER histology codes: 8000–
8152, 8154–8231, 8243–8245, 8250–8576, 8940–8950,
and 8980–8981). Those who underwent primary tumor
resection with likely curative intent within 180 days of
diagnosis were selected, excluding presumably palliative
operations. Data of all patients who received preoperative
(from diagnosis of rectal cancer to operation) radiotherapy
plus 5-FU or capecitabine, which was the regimen recom-
mended by the NCCN, were included. Regarding the post-
operative chemotherapy, the no-chemo group included
patients with no record for chemotherapy within 120 days
of surgery. The oxaliplatin group included patients with
any record of oxaliplatin within 30 days of their first
chemotherapy dose. The 5-FU group comprised all
other patients, including those who received 5-FU or
capecitabine. The Health Care Financing Administra-
tion Common Procedure Coding System or National
Drug Code for drugs were presented in Additional file 1.
Patients were excluded from this study if they (1) re-
ceived other chemotherapy regimen preoperatively or
postoperatively; (2) had prior non-rectal cancer; (3) had
incomplete pathological stage entries or diagnostic data;
(4) died during the immediate postoperative period
(within 30 days); (5) were diagnosed with another malig-
nancy 1 year after the date of rectal cancer diagnosis; (6)
had membership in a Medicare-sponsored health main-
tenance organization or lack of enrollment in Medicare
Parts A and B from 12 months preceding diagnosis
through 9 months after diagnosis; (7) had complete
pathologic response because it was unable to identify ac-
curately in the SEER-Medicare database; and (8) had
ypStage 0 (Tis N0 M0), because of too small sample size.
Variables
Age at diagnosis, year of diagnosis, sex, race, marital sta-
tus, rural/urban county of residence, census tract-level
median household income, and level of education (per-
centage of people aged >25 years and <12 years of educa-
tion) were obtained from the SEER patient entitlement
and diagnosis summary file. For risk adjustment, Centers
for Medicare and Medicaid Services Hierarchical Condi-
tion Categories (HCC) based on outpatient and inpatient
diagnoses from the 12 months before rectal cancer diag-
nosis were used. The resulting score can be interpreted as
a patient’s predicted level of “future health care need” rela-
tive to the average Medicare beneficiary (HCC = 1.0) [21].
Patients were staged according to the seventh edition of
the Union for International Cancer Control (UICC) tumor-
node-metastasis (TNM) staging system [22]. Postoperative
pathological stage (ypTNM) was used. The preoperative




Male 448 321 131
Female 324 219 92
Age at diagnosis, years
66-70 201 184 105
71-75 234 175 70
>75 337 181 48
Residence location
Big Metro 383 261 127
Metro or Urban 303 199 77
Less Urban or Rural 86 80 19
Year of diagnosis
1992-1996 17 10 0
1997-2000 132 115 0
2001-2004 296 251 26
2005-2008 327 164 197
Histologic grade
Well 59 35 14
Moderate 519 360 146
Poor/Undifferentiated 116 87 37
Unknown 78 58 26
ypT category
ypT1-2 261 146 50
ypT3 446 367 160
ypT4 65 27 13
ypN category
ypN0 609 339 134
ypN1a 79 85 34
ypN1b 42 59 26
ypN2a 20 36 16
ypN2b 22 21 13
ypTNM stage
ypTNM I 233 113 36
ypTNM II 376 226 98
ypTNM III 163 201 89
Intestinal obstruction
No 677 484 201
Yes 95 56 22
HCC risk score
1st quartile 210 143 56
2nd quartile 157 131 45
3rd quartile 189 152 67
4th quartile 216 114 55
Table 1 Clinicopathologic features of patients with
different chemotherapy regimens (Continued)
Number of examined lymph node
≥12 265 200 106
<12 507 340 117
Postoperative radiotherapy
No 676 455 208
Yes 96 85 15
Abbreviations: HCC Hierarchical Condition Categories, No-chemo without
postoperative chemotherapy, 5-FU 5-fluorouracil.
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Other covariates included were tumor grade, histological
type, preoperative intestinal obstruction, preoperative intes-
tinal perforation, postoperative radiotherapy, and the num-
ber of lymph nodes examined.
Statistical analysis
In the univariable analysis, the cancer-specific (CSS) was
analyzed by Kaplan-Meier survival curves, and compari-
sons were made by the log-rank test stratified by the
ypTNM stage.
In clinical practice, significant differences exist between
patients who are and are not treated with chemotherapy,
particularly with regard to age and comorbidities. Because
treatment effect estimates are likely confounded by factors
related to treatment selection, a propensity score (PS)-
matched analysis was performed to compare the effect of
treatment on survival among patients of similar risk pro-
files as assessed by measured known confounders [23,24].
For this analysis, logistic regression models were built for
each stage to estimate each patient’s probability of receiv-
ing 5-FU or oxaliplatin, conditional on covariates. Later
two PSs were generated: one estimated the likelihood of
5-FU receipt and the other estimated the likelihood of
oxaliplatin receipt in chemotherapy-treated patients. For
each comparison, patients exposed to treatment (5-FU
and oxaliplatin) were matched with patients with the same
PS from the unexposed treatment group. Patients for
whom there was no match were excluded. In this manner,
a PS-matched cohort balanced across treatment groups
for measured confounders was generated. The CSS was
then compared in these PS-matched cohorts using the
log-rank test stratified by the ypTNM stage.
As the sample size was moderate, a Cox proportional
hazards model was also used in the adjusted analysis. The
covariates included all variables that were identified to be
significantly related to survival in the univariable analysis
and the tests were made stratified by the ypTNM stage.
All statistical analyses and graphics were performed by
the lead author using SAS 9.3 (SAS Institute, Cary, NC,
USA), STATA 12.0 software (STATA, College Station,
TX, USA), and PASW Statistics 18.0 software (SPSS, Inc.,
Figure 1 Kaplan-Meier comparison of cancer-specific survival
among patients who received different postoperative
treatment stratified by pathologic stage. A. ypStage I;
B. ypStage II; C. ypStage III.
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ered to indicate a significant result.
Results
Patient demographics
A total of 1535 patients with resected rectal cancer who
received neoadjuvant chemoradiotherapy regimen rec-
ommended by the NCCN were included (Table 1). De-
tails of race, marital status, median household income,
level of education, histologic type, and intestinal perfor-
ation were not presented in Table 1, because the number
of patients in some subgroups was too small and the
SEER-Medicare rules require that cell sizes less than
eleven in a table must be suppressed.
CSS without chemotherapy or with 5-FU
The unmatched 5-year CSS rates for the patients in the
no-chemo group were 90.6%, 78.8%, and 49.5% as com-
pared with 90.9%, 84.0%, and 59.0% for the 5-FU group in
ypStage I (T1-2 N0 M0), II (T3-4 N0 M0), and III (Any T
N1-2 M0), respectively (Figure 1). There was no signifi-
cant difference in survival between two groups in ypStage
I (P = 0.961) and ypStage II (P = 0.109). The prognosis of
patients in the no-chemo group was significantly worse
than the 5-FU group in ypStage III (P = 0.024).
The variables that were significantly related to the pa-
tients’ probability of receiving 5-FU were presented in
Additional file 2. The PS-matched cohorts were generated
using these variables. The CSS was then compared in
these PS-matched cohorts. There were still no significant
differences in survival between the two groups in ypStage
I (P = 0.884) and ypStage II (P = 0.345), but for patients in
ypStage III the prognosis of the no-chemo group was sig-
nificantly worse than the 5-FU group (P = 0.009; Figure 2).
A Cox proportional hazards model was also used for
comparison of survival between the two groups. The co-
variates included all variables that were identified to be
significantly related to survival (Additional file 3). The
results were consistent with that of the PS-matched
analysis, and in ypStage III, the patients in the no-
chemo group was significantly worse than the 5-FU
group (hazard ratio = 1.547, 95% CI = 1.101-2.173, P =
0.012; Table 2).
CSS with or without oxaliplatin
The unmatched 5-year CSS rates for the patients in the
oxaliplatin group were 91.1%, 87.9%, and 73.7% as com-
pared with 90.9%, 84.0%, and 59.0% for the 5-FU group
in ypStage I, II, and III, respectively (Figure 1). There
were no significant differences in survival between the
two groups in all stages (P ≥; 0.05).
The variables that significantly related to the patients’
probability of receiving 5-FU plus oxaliplatin compared
with 5-FU alone were presented in Additional file 2.
Figure 2 After PS-matched, Kaplan-Meier comparison of cancer-specific survival between patients in the no-chemo group and in the
5-FU group stratified by pathologic stage. A. ypStage I; B. ypStage II; C. ypStage III.
Gao et al. BMC Cancer 2014, 14:888 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/888The PS-matched cohorts were generated using these
variables. The CSS was then compared in these PS-
matched cohorts. There were still no significant differ-
ences in survival between the two groups in all stages
(P > 0.05; Figure 3).
A Cox proportional hazards model was also used for
comparison of survival between the two groups. The co-
variates included all variables which were identified to
be significantly related to survival (Additional file 3).
The results showed that there were still no significant
differences in survival between the two groups in all
stages (Table 2).
Discussion
Preoperative chemoradiotherapy is the standard treatment
for locally advanced rectal cancer. However, there is no
general agreement about whether patients who have
already received neoadjuvant chemoradiotherapy need fur-
ther postoperative chemotherapy based on 5-FU. Janjan
[25] proposed that there was significant improvement in
CSS in response to preoperative chemoradiotherapy and
the administration of adjuvant chemotherapy. Collette [15]
analyzed a subset of data from the European Organization
for Research and Treatment of Cancer (EORTC) Trial
22921, which revealed that the postoperative 5-FU-based
chemotherapy prolonged survival in ypT0-2, but not in
ypT3-4, patients. Hypothetically, distal micrometastasis
may be cleared by chemotherapeutic drugs more effectively
in patients who were good in response (in low ypStage) to
preoperative chemoradiotherapy.
However, Das [26] proposed that postoperative chemo-
therapy may be of greater benefit for patients in a higher
ypStage such as ypStage III (ypN1-2), and lower ypStage
subgroups should receive a relatively conservative thera-
peutic regimen. Subsequently, a study by Huh [11] re-
vealed that postoperative adjuvant chemotherapy for
patients in ypT0-2 N0 classification after preoperativechemoradiation and curative surgery did not significantly
improve the survival, which was consistent with the sugges-
tion of Das [26], but these results contradictory to that of
Collette [15]. Later the results of the study by Govindarajan
[9] confirmed that there was no significant difference in
the 5-year DFS between patients, in ypT0-2 N0 and
ypT3-4 N0 classifications, who did and did not receive
adjuvant treatment. In addition, both Fietkau [10] and
Kiran [12] proposed that adding postoperative chemo-
therapy did not significantly improve the survival of pa-
tients in ypN0 classification. More recently, Bosset [14]
completed the EORTC Trial 22921 and proposed that
postoperative 5-FU-based chemotherapy after preope-
rative radiotherapy (with or without chemotherapy)
did not affect DFS or OS. The result was confirmed
in both ypT0-2 and ypT3-4 classifications; however,
this analysis was not stratified on the basis of ypN
classification.
Although the conclusions of the aforementioned studies
were different, a consensus may be arrived at based on the
postoperative pathologic stage of the patient in determin-
ing the need for adjuvant chemotherapy. Simultaneously,
several studies proposed that the risk of distant metastases
is directly proportional to the postoperative pathologic
stage [9,27-29], and Quah [28] found that the outcome
was most accurately estimated by the postoperative patho-
logic stage. Nevertheless, the NCCN recommended post-
operative chemotherapy for all patients undergoing
preoperative chemoradiotherapy regardless of the results
of the surgical pathology tests [7].
Considering the importance of ypTNM stage in deter-
mining the need for adjuvant chemotherapy, all tests were
made stratified by ypTNM stage. We compared the prog-
nosis among patients in no-chemo, 5-FU, and oxaliplatin
group in the unmatched univariable survival analysis. We
found that postoperative 5-FU-based chemotherapy did
not prolong the CSS in ypStage I (ypT1-2 N0) (Figure 1A)






No-chemo 1.021 0.459-2.273 0.960




ypT4a 1.187 0.291-4.841 0.811
ypT4b 1.878 1.058-3.334 0.031
Postoperative radiotherapy
No 1
Yes 1.870 1.159-3.018 0.010
Histologic type
Adenocarcinoma 1
Mucinous carcinoma 1.877 1.138-3.094 0.014
Signet-ring cell carcinoma 8.078 2.351-27.748 0.001
Chemotherapy regimens
5-FU 1
No-chemo 1.393 0.903-2.148 0.134
Oxaliplatin 0.926 0.438-1.956 0.840
Stage III
ypT category
ypT1 1.150 0.491-2.692 0.747
ypT2 0.759 0.436-1.321 0.329
ypT3 1
ypT4a 0.691 0.244-1.959 0.487
ypT4b 1.592 0.934-2.713 0.088
ypN category
ypN1a 1
ypN1b 1.233 0.825-1.844 0.306
ypN2a 1.468 0.905-2.381 0.119
ypN2b 2.098 1.310-3.357 0.002
Residence location
Big Metro 1
Metro or Urban 1.147 0.822-1.600 0.419
Less Urban or Rural 0.487 0.257-0.923 0.027
Histologic type
Adenocarcinoma 1
Mucinous carcinoma 1.466 0.993-2.163 0.054
Signet-ring cell carcinoma 1.220 0.459-3.239 0.690
Histologic grade
Well 0.716 0.229-2.239 0.565
Table 2 Cox proportional hazards model stratified by
ypTNM stage (Continued)
Moderate 1
Poor 1.650 0.753-3.619 0.211
Undifferentiated 2.817 0.891-8.910 0.078
Unknown 1.037 0.496-2.171 0.922
Chemotherapy regimens
5-FU 1
No-chemo 1.547 1.101-2.173 0.012
Oxaliplatin 0.626 0.372-1.054 0.078
Abbreviations: No-chemo without postoperative chemotherapy, 5-FU 5-
fluorouracil, CI Confidential intervals.
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to the study by Govindarajan [9]. On the contrary, ad-
ding postoperative 5-FU-based chemotherapy significantly
improved survival of patients in ypStage III (ypN1-2)
(Figure 1C). To the best of our knowledge, the outcome of
postoperative 5-FU-based chemotherapy in ypStage III pa-
tients was never reported previously, although researchers
stressed the need for a randomized clinical trial [30,31].
To confirm our results, both the PS-matched analysis and
the Cox proportional hazards model were used to make
adjusted analysis, and the results were in accordance with
the univariable survival analysis (Figure 2, Table 2).
Adding oxaliplatin to fluoropyrimidines in the adjuvant
setting improved the OS in colon cancer compared with
FU and leucovorin regimens [32]. According to the
NCCN guidelines, for patients with resected rectal cancer
who have already received 5-FU-based neoadjuvant che-
moradiotherapy, 5-FU/leucovorin/oxaliplatin (FOLFOX)
was an optional regimen for postoperative chemotherapy.
Several ongoing randomized clinical trials in rectal cancer
focused on improving 5-FU-based chemotherapy through
the addition of oxaliplatin preoperatively, postoperatively,
or both [16,17,33-35]. Two study groups presented pre-
liminary results. Hong [17] proposed that postoperative
FOLFOX significantly improved the 2-year DFS relative to
postoperative 5-FU-based chemotherapy for rectal cancer
patients in ypStage II or III after 5-FU-based neoadjuvant
chemoradiotherapy followed by TME. On the contrary,
Nimeiri [16] discovered that there was no difference in
the OS between patients who received 5-FU alone or
FOLFOX as postoperative chemotherapy. In the current
study, no significant differences were found in the survival
between the two groups (5-FU vs. oxaliplatin) of patients
with resected rectal cancer who have already received 5-
FU-based neoadjuvant chemoradiotherapy (Figures 1 and
3; Table 2). Although this result need to be confirmed by
further clinical trials, we argue that, for patients who re-
ceived neoadjuvant chemoradiotherapy, adding oxaliplatin
to fluoropyrimidines in the postoperative chemotherapy
require serious consideration at present.
Figure 3 After PS-matched, Kaplan-Meier comparison of cancer-specific survival between patients in the 5-FU group and in the
oxaliplatin group stratified by pathologic stage. A. ypStage I; B. ypStage II; C. ypStage III.
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was a retrospective exploratory study, the potential for
confounding based on patient selection could not be
eliminated. Both traditional Cox proportional hazards
model and PS-matched techniques were used to ac-
count for known relevant confounders. Second, only
patients aged ≥66 years at the time of diagnosis were
included in this study, which may limit the applicabil-
ity of the findings to younger patients with rectal can-
cer. Third, the role of several known prognostic
features such as tumor regression grade, preoperative
carcinoembryonic antigen, microsatellite instability, peri-
neural invasion, and lymphovascular invasion could not be
investigated, as these characteristics were not available
within the SEER-Medicare database. Patients with pCR
were excluded from analysis because the pCR status was
not well supported by the SEER-medicare database. Fourth,
this study retrospectively examined the use of chemother-
apy as identified through the Medicare claims data using a
“one-claim” algorithm [36,37]. This created a heteroge-
neous population in which some patients received a sub-
standard duration of therapy. However, O'Connor [38]
proposed that the “none versus any” approach used to as-
sign treatment status provided a window into the effective-
ness of chemotherapy in real-world practice, in which an
individual’s likelihood of completing the treatment course
is not known at the outset of the study. Finally, the pre-
operative clinical stage as well as pathologic response to
neoadjuvant therapy was not supported by the SEER-
Medicare database. Both the preoperative clinical stage and
pathologic response were related to outcome; however,
Quah [28] found that the outcome was most accurately
estimated by the postoperative pathologic stage and the
clinical stage adds no predictive value to the prognosis.
In addition, the 100% accuracy of clinical staging was un-
tenable even in the best of centers [39]. Based on this,
the decision of postoperative chemotherapy could beregarded mainly as based on postoperative pathologic
stage.
Conclusions
It is concluded that, for patients with resected rectal can-
cer who have already received 5-FU-based neoadjuvant
chemoradiotherapy, postoperative 5-FU-based chemo-
therapy prolongs the CSS of groups in ypStage III. Add-
ing oxaliplatin to fluoropyrimidines in the postoperative
chemotherapy did not improve the CSS for patients who
received neoadjuvant chemoradiotherapy.
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